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Abstract 
Background: Rising evidence indicate that oxytocin and IL‑1β impact trigemino‑nociceptive signaling. Current 
perspectives on migraine physiopathology emphasize a cytokine bias towards a pro‑inflammatory status. The anti‑
nociceptive impact of oxytocin has been reported in preclinical and human trials. Cervical non‑invasive vagus nerve 
stimulation (nVNS) emerges as an add‑on treatment for the preventive and abortive use in migraine. Less is known 
about its potential to modulate saliva inflammatory signaling in migraine patients. The rationale was to perform 
inter‑ictal saliva measures of oxytocin and IL‑1ß along with headache assessment in migraine patients with 10 weeks 
adjunctive nVNS compared to healthy controls.
Methods: 12 migraineurs and 12 suitably matched healthy control were studied with inter‑ictal saliva assay of pro‑ 
and anti‑neuroinflammatory cytokines using enzyme‑linked immuno assay techniques along with assessment of 
headache severity/frequency and associated functional capacity at baseline and after 10 weeks adjunctive cervical 
nVNS.
Results: nVNS significantly reduced headache severity (VAS), frequency (headache days and total number of attacks) 
and significantly improved sleep quality compared to baseline (p < 0.01). Inter‑ictal saliva oxytocin and IL‑1β were 
significantly elevated pre‑ as well as post‑nVNS compared to healthy controls (p < 0.01) and similarly showed changes 
that may reflect the observed clinical effects.
Conclusions: Our results add to accumulating evidence for a therapeutic efficacy of adjunct cervical non‑invasive 
vagus nerve stimulation in migraine patients. This study failed to provide an evidence‑derived conclusion addressed 
to the predictive value and usefulness of saliva assays due to its uncontrolled study design. However, saliva screening 
of mediators associated with trigemino‑nociceptive traffic represents a novel approach, thus deserve future targeted 
headache research.
Trial registration This study was indexed at the German Register for Clinical Trials (DRKS No. 00011089) registered on 
21.09.2016
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Background
Migraine represents a devastating primary headache dis-
order affecting approximately 14% of the population with 
an emerging prevalence and socio-economic burden [1–
4]. The distinction and definition of episodic and chronic 
migraine has been an issue of ongoing debate [5, 6]. For 
instance, both have been reported to differ in preva-
lence, symptom profile, socio-demographics, individual/
economic burden and co-morbidities [6]. However, pre-
ventive and abortive pharmacological/behavioral inter-
ventions overlap in both migraine subtypes and failed to 
achieve favorable response in a considerable proportion 
of migraineurs [6–8]. Thus, cervical non-invasive vagus 
stimulation (nVNS) has been approved to represent a rea-
sonable and safe adjunctive treatment option for preven-
tion and abortive migraine therapy [9–16]. In two RCT 
trials, the EVENT study (chronic migraine prevention 
with non-invasive vagus nerve stimulation) and PRESTO 
study (prospective study of nVNS for the acute treat-
ment of migraine) and several prospective observational 
cohort studies, nVNS demonstrated the capability to 
effectively act as adjunctive prophylaxis and rescue inter-
vention in episodic and chronic migraine as well as in 
associated mood and sleep disturbance [10–12, 16–19]. 
Further long-term follow-up observations by Martelletti 
and colleagues and an additional post hoc analysis con-
firmed the initial findings of the PRESTO study [17, 18]. 
Interestingly, transcutaneous stimulation of the auricu-
lar branch of the vagal nerve (t-VNS) at 1 Hz promoted 
a significantly larger reduction of chronic migraine fre-
quency compared to 25 Hz t-VNS. Of note, t-VNS dura-
tion lasted for 4  h per day during the 3  months study 
period [19]. In order to parallel acute and chronic head 
pain and to investigate possible VNS-induced changes 
in the trigemino-nociceptive system, several preclinical 
studies confirmed the clinical observed VNS responsive-
ness, although the precise pathways are not fully under-
stood [20–28].
Oxytocin is synthesized in neurons exclusively located 
within the hypothalamic nuclei (nucleus paraventricu-
laris of the hypothalamus; PVN) and the supraoptic 
nucleus (SOP). Magnocellular neurons are distributed 
in the PVN and in the SOP and project to the posterior 
pituitary lobe (release oxytocin into the blood flow) and 
secondly, these neurons are connected with brain areas 
such as the amygdala, hippocampus, and cerebral cor-
tex. A smaller population of parvocellular oxytocinergic 
neurons associated with the PVN interacts via receptor 
signaling with the brainstem and the spinal cord (dorsal 
column layers/dorsal root ganglion), but not via systemic 
blood circulation. Thus, through both pathways, oxy-
tocin has been suspected to impact central and periph-
eral nociceptive transmission and neuro-inflammatory 
pain signaling [29–31]. Observational studies exam-
ined migraine relief after oxytocin administration in 
the past [32, 33]. Tzabazis and colleagues investigated 
the anti-nociceptive head pain potential of oxytocin in 
preclinical and human trials [34, 35]. Remarkably, after 
administration of radiographic labeled oxytocin, high 
concentrations were tracked in the trigeminal nucleus 
caudalis (TNC), the trigeminal ganglion (TG) and cor-
responding three trigeminal branches (V1–V3), which 
innervate the corresponding mucosa and glandulae [35].
Earlier reports applying VNS for depression and sei-
zure observed peripheral changes of pro-/anti-inflam-
matory cytokines (IL-1β, TNF-α) in small-scale cohorts 
[36, 37]. Of interest, ictally elevated IL-1β concentra-
tions were observed in the jugular blood of migraine 
patients [38]. Perini and et al. demonstrated intra-ictally 
elevated levels of IL-1β and TNF-α in migraine patients 
compared to healthy controls, which was re-examined in 
a most recent cytokine migraine study [39, 40]. In addi-
tion, nVNS significantly decreased serum concentrations 
of IL-1β (pro-inflammatory) and increased anti-inflam-
matory marker IL-10 compared to sham stimulation in 
healthy individuals [41]. Although not fully understood, 
experimental data indicate that IL-1β promotes activa-
tion of trigemino-nociception and peripheral/central 
neuro-inflammatory pathways involved in headache 
onset [42–46].
This is the first study assessing saliva oxytocin and 
IL-1β concentrations along with score-based assess-
ment of clinical responsiveness [head pain severity, fre-
quency (headache days-attacks/month), functional state 
(sleep quality, mood, quality of life)] in migraine patients 
treated with adjunctive cervical nVNS.
Methods
Study design
The rationale of this prospective observational case con-
trol study was to investigate the efficacy of nVNS as an 
adjunct to medication in patients with treatment-refrac-
tory episodic migraine (EM) and chronic migraine (CM). 
In addition to a variety of functional outcome measures, 
interictal (defined as 48  h apart from an attack) saliva 
concentrations of pro-inflammatory cytokine IL-1ß and 
anti-inflammatory oxytocin were assessed at baseline 
(pre-nVNS) and re-assessed after 10 weeks of adjunctive 
nVNS treatment (post-nVNS).
Ethics, consent, permissions
This study was performed according to the guidelines 
of the latest revision of the declaration of Helsinki. Eth-
ics approval for this study was obtained from the insti-
tutional review board (Ethic Commission University 
Hospital Bonn IRB no.: 296/15). All patients provided 
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written informed consent. Furthermore, the study was 
pre-registered at the German Register for Clinical Trials 
(DRKS No. S00011089).
https ://www.drks.de/drks_web/navig ate.do?navig ation 
Id=trial .HTML&TRIAL _ID=DRKS0 00110 89.
Study population and clinical assessment
The study enrollment was from September to October 
2016. The patients were assigned by a headache special-
ist (anesthesiologist/neurologist) to our university hospi-
tal. In addition, the diagnosis of the refractory headache 
disorder was confirmed from an interdisciplinary inter-
nal pain board (including a neurologist, an anesthesi-
ologist, a neurosurgeon, psychiatrist, and pain nurse) in 
cooperation with a tertiary level headache center accord-
ing to the criteria listed of the International Classifica-
tion of Headache Disorders (ICHD; third edition; beta). 
In particular, the terms refractory and drug-resistant 
migraine are still highly debated [1, 47, 48]. The patients 
were refractory to four classes of preventive medication 
and/or experienced side-effects (β-blockers, anticonvul-
sants, tricyclic antidepressants, calcium channel block-
ers) using different dosages of rescue drugs. In addition, 
10 (2 CM/8 EM) patients out of 12 patients experienced 
a less favorable outcome with the usage of botulinum 
toxin. Of note, botulinum toxin represents off label in 
EM and probably not effective in EM. Standard medica-
tion was stable 4 weeks prior to baseline visit according 
to the individual’s prescriptions and remained unchanged 
through the entire study period. Depending on their 
intensity, migraine attacks were categorized as severe 
(severe = VAS 7–10/10, moderate = VAS 4–6/10 or 
mild = VAS 1–3/10). Inclusion and exclusion criteria are 
outlined in Table 1.
Functional outcome measures collected at baseline 
(pre-nVNS) and after accomplishment of 10 weeks nVNS 
treatment (post-nVNS) evaluating the mean change from 
baseline in patient-reported head pain intensity (visual 
analogue scale, VAS) and frequency (mean change in 
number of headache days and attacks compared to base-
line). Baseline values for number of headache days and 
migraine attacks per month were assessed on the basis of 
patient self-report/headache diaries and medical records 
Participants recorded functional outcome measures dur-
ing the 10 weeks of nVNS treatment on a daily basis. In 
addition to patients’ self-report (headache diaries), clini-
cal outcome measures were assessed through interviews 
during the outpatient visits in the 11th week after base-
line in an inter-ictal period (defined as 48  h apart from 
an attack). Data of all reported and treated attacks within 
the 10 weeks of nVNS therapy were pooled and analyzed. 
Relevant migraine co-morbidities including impaired 
sleep quality (Pittsburgh Sleep Quality Index, PSQI), 
depressive symptoms (Beck Depression Inventory, BDI), 
health status (EuroQuol EQ-5D-5L), impact of headache 
on life (Migraine Disability Assessment, MIDAS) and 
Body Mass Index (BMI) [49, 50]. Pain relief was defined 
as a ≥ 50% reduction in severity and/or frequency of 
attacks.
Demographic and baseline characteristics
Of the 14 participants initially enrolled in the study, two 
patients were excluded from analysis due to protocol vio-
lation, such that the final analysis included data acquired 
from 12 patients. One participant changed pain medica-
tion and another discontinued nVNS due to temporary 
skin discomfort. All patients were female with a mean 
age of 47.6 years (range 34–65 years). The majority pre-
sented with EM (n = 10, five with aura) and two patients 
presented with CM (with aura) (Table 2).
Eleven patients were classified as MIDAS grade III/
IV and one patient was classified as grade I. Evaluation 
of sleep patterns at baseline revealed that 10/12 (83%) 
patients had a disturbed sleep architecture measured 
by a PSQI > 5 points. Furthermore, mood disturbances 
indexed by a BDI score > 12 occurred in 9/12 (75%) 
patients, with 4/12 (33%) exhibiting at least moderate 
Table 1 Inclusion and exclusion criteria according to the study protocol
Inclusion criteria Exclusion criteria
Chronic refractory headache disorder according to the International Clas‑
sification of Headache Disorders ICHD (third edition; beta)
Age equal/greater 18
Informed consent (Study, nVNS)
Refractory to medical and/or behavioural therapy
Medication overuse headache has been ruled out
Eligible for vagus nerve stimulation
Willingness to a defined follow‑up interval
Intracranial and cervical pathologies excluded by MR scan
Standard medication 4 weeks prior to nVNS and within the entire study 
period according to the individual’s prescriptions
No informed consent
Other concomitant neuropsychiatric comorbidity not adequate classified 
and/or requiring specific diagnosis or treatment
Pregnancy
Malignancy
Previous performed invasive, noninvasive and ablative procedure
Not willing to complete pain diary regarding severity and frequency
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depressive symptoms (BDI score > 19). All patients pre-
sented with BMI values < 30 kg/m2 (Table 3).
Baseline assessment of the healthy control group (HC) 
demonstrated similar characteristics compared to the 
migraine group (14 females; mean age, 46.9 years, rang-
ing from 22 to 59 years, BMI 22.1 ± 1.7).
Sample collection and laboratory assessment
Saliva samples from patients were collected at a stand-
ardized time (8.00–9.00 a.m.) in the morning (at baseline 
and again after 10  weeks of nVNS) in fasting condition 
in an inter-ictal interval (defined as 48  h apart from an 
ictus). Cytokine levels were assessed using high-sensitiv-
ity ELISA kits obtained from BD Biosciences Cell Analy-
sis (IL-1β) (Heidelberg, Germany). Saliva samples were 
collected using pre-chilled Salivettes (Sarstedt, Nuem-
brecht, Germany). Salivettes were immediately centri-
fuged at 4180g for 2  min and aliquoted samples were 
stored at − 80  °C until assayed. Salivary OXY concen-
trations were determined by using a 96 well commercial 
Table 2 Demographic data and  baseline characteristics of  the  study population addressed to  severity, frequency 
and current preventive and abortive medication
f female, VAS visual analogue scale, CM chronic migraine, EM episodic migraine, ± with/without Aura, TRIP triptans, TCA tricyclic Antidpressants, SSRI Selective 
Serotonin reuptake inhibitor, NSAD nonsteroidal anti-inflammatory drugs, ASS acetylsalicylic acid, nVNS cervical non-invasive vagus nerve stimulation, preVNS 
medication remained stable 4 weeks prior to study enrollment (see inclusion criteria)












1 CM+ 10 7/10 18 None TRIP + NSAD
2 EM+ 12 5/10 12 ß‑blocker + TCA TRIP + NSAD
3 EM− 5 7/10 9 ß‑blocker + TCA TRIP
4 EM− 12 8/10 14 None TRIP
5 CM+ 16 8/10 26 None TRIP
6 EM− 7 6/10 9 None TRIP
7 EM+ 2 8/10 8 None TRIP + NSAD
8 EM− 11 7/10 12 None NSAD
9 EM+ 10 8/10 10 Magnesium TRIP + NSAD
10 EM+ 3 8/10 3 SSRI TRIP + NSAD
11 EM+ 8 8/10 14 ß‑blocker + TCA TRIP
12 EM− 10 9/10 14 ß‑blocker TRIP + ASS
Table 3 Functional state (body weight, sleep, mood, quality of  life) and  saliva concentrations of  oxytocin and  IL-1ß 
at baseline
BDI Becks depression inventory, BMI body mass index, CM chronic migraine, EM episodic migraine, EQ-5D-5L EuroQol five-dimensional five level scale, f female, MIDAS 
Migraine Disability Assessment, PSQI Pittsburgh Sleep Quality Index
Patient no BMI kg/m2 Migraine Type MIDAS score/
grade





1 22 CM+ 93/IV 25 8 12 61.6 215
2 19 EM+ 13/III 2 2 6 27.5 195
3 23 EM− 92/IV 23 10 15 24.1 1000
4 27 EM− 39/IV 20 10 5 29.6 822
5 28 CM+ 73/IV 44 13 18 105.3 334
6 20 EM− 40/IV 12 10 8 20.6 194
7 24 EM+ 51/IV 7 9 9 16.3 168
8 22 EM− 2/I 9 10 7 41 261
9 28 EM+ 47/IV 6 13 7 120.7 1000
10 27 EM+ 16/III 12 7 11 16.9 272
11 24 EM+ 106/IV 10 19 14 44.2 730
12 19 EM− 17/III 0 4 8 22.7 262
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oxytocin ELISA kit (IBL, Hamburg, Germany). Measure-
ments were performed in duplicate, and samples were 
treated following kit instructions. According to the man-
ufacturer, the sensitivity limit of the assay is 11.7 pg/ml. 
The assay’s intra-assay and inter-assay coefficients of vari-
ability are 9.1–12.4% and 5.2–14.5%, respectively.
Saliva samples for OXY and IL1ß were obtained from 
a healthy control group (HC) consisting of 14 females 
(mean age, 46.9 years; range 22–59 years) matching the 
demographic characteristics of the treatment group. For 
reliability reasons two saliva samples per person were 
measured and the mean value was used for further calcu-
lations. Lin’s concordance correlation coefficient for the 
two saliva samples showed sufficient reliability (r = 0.67, 
p < 0.01). Healthy controls were recruited from the local 
population by means of online advertisement, public 
postings and contacts to assisted living facilities. Subjects 
were free of any current physical or psychiatric illness 
as assessed by medical history. After completion of the 
study, participants received monetary compensation.
Cervical nVNS stimulation paradigm
Cervical nVNS (gammaCore) received CE-marked 
approval for the acute and preventive treatment of pri-
mary headache disorders (migraine, cluster headache) 
and medication-overuse headache and was approved 
by the US Food and Drug Administration for the acute 
treatment of episodic cluster headache and acute pain 
associated with migraine.
Patients self-administered bilateral (first right–second 
left) nVNS therapy twice daily, i.e. each morning and 
afternoon. Self-stimulation lasted for 120  s. For attack 
treatment, patients were instructed to administer one 
additional bilateral application at the onset of each head-
ache attack in conjunction to medication. An appropriate 
and standardized patient instruction of the nVNS device 
was supervised from the same instructor at baseline and 
throughout the entire study period.
The nVNS device was positioned medially to the ster-
nocleidomastoid muscle and laterally to the larynx, with 
the following stimulation specifications: 1-ms bursts of 
5 kHz sine waves, repeated every 40 ms (25 Hz) with an 
adjustable stimulation intensity (from 0 to 24 V). A con-
ducting gel was applied in order to ensure transdermal 
signal conductivity.
Statistical analysis
Normality of the data was assessed by a Shapiro–
Wilk test. Normally distributed data are presented as 
mean ± SEM, while non-normally distributed data are 
presented as box plots with whiskers showing minimum 
and maximum values. Pearson’s correlation coefficients 
were used to assess linear associations between different 
parameters, while Spearman’s correlation coefficients 
were determined to assess non-linear associations. A p 
value < 0.05 was considered significant. The data was ana-
lyzed using GraphPad Prism 5.00 (San Diego California, 
USA).
Results
nVNS and migraine-associated head pain severity 
and frequency
The mean VAS score decreased from 7.4 ± 0.3 at base-
line to 5 ± 0.2 (p < 0.01, 95% CI 4.6–5.4) (Fig.  1a). The 
mean number of headache days in the nVNS group was 
12.5 ± 1.7 at baseline and 8.7 ± 1.3 (p < 0.01; 95% CI 5.8–
11.5) at the 11th week (end of nVNS treatment), while 
the number of attacks declined from 9.1 ± 1.5 at baseline 
to 5.9 ± 0.8 at the end of nVNS therapy (p < 0.01; 95% CI 
4.1–7.7) (Fig. 1b, c).
The total number of attacks decreased by 1/3 from 
109 (24 mild–42 moderate–43 severe) at baseline to 71 
(16 mild–38 moderate–17 severe), with a 60% reduction 
in the percentage of severe attacks (Fig.  2). At baseline, 
only one patient achieved pain freedom within 2 h after 
treatment with acute medication. Following 10  weeks 
of adjunctive nVNS therapy, the proportion of patients 
achieving pain freedom climbed to 4.
nVNS and migraine-associated depressive symptoms, 
impairment of functional capacity and sleep architecture
Migraine-related abnormalities in sleep architecture 
as assessed by the PSQI improved after nVNS therapy 
(9.6 ± 1.3 to 6.7 ± 1.1; p < 0.01; 95% CI 4.3–9.0) (Fig. 1d). 
Functional capacity measured by the MIDAS score, 
migraine-associated clinical depressive symptoms quan-
tified by the BDI score and the EQ-5D-5L, however, did 
not change [BDI (baseline mean 14.2 vs post nVNS 12.6; 
p = 0.77) and EQ-5D-5L (baseline mean 10.0 vs post 
nVNS 9.3); p = 0.64] (Table 4).
nVNS effects on saliva concentrations of oxytocin and IL-1ß
Pre-nVNS oxytocin levels were more than doubled than 
those measured in healthy controls (HC: 20.4 ± 1.7 pg/ml 
vs pre-nVNS patients: 44.2 ± 10.1 pg/ml; p < 0.05; 95% CI 
22.1–66.3) and increased without significant difference 
after nVNS therapy (pre-nVNS patients: 44.2 ± 10.1  pg/
ml vs post-nVNS patients: 46.6 ± 12.6  pg/ml) (Fig.  3a). 
Cytokine saliva levels of IL-1β increased after nVNS ther-
apy, yielding 2.5 times higher values than those meas-
ured in healthy controls (p < 0.05) (HC: 199.9 ± 41.4  pg/
ml vs pre-VNS patients: 345.3 ± 73.3 pg/ml vs post-nVNS 
patients: 490.7 ± 113.1  pg/ml; p < 0.05, 95% CI 234.6–
746.5) (Fig. 3b).
Assessment of cumulative pre- and post-nVNS oxy-
tocin levels showed a trend towards association with the 
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headache days per month (r = 0.379, p = 0.08) (Fig.  4), 
but not with number of attacks per month (r = 0.343, 
p = 0.12) (Fig. 5). By contrast, no significant correlation or 
trend between global salivary IL-1β and migraine assess-
ment parameters was observed. Prior to nVNS treatment 
and within the treatment period no clinical systemic dis-
ease was observed (CRP below 0.4 mg/dl).
nVNS associated adverse events
Two patients reported mild treatment-related adverse 
events (AEs), most commonly skin irritation. No severe 
or serious AEs occurred.
Discussion
Brief summary of study findings and comparison 
with available literature
Our findings add to pre-existing evidence for the poten-
tial therapeutic value and safety of the preventive and 
acute use of nVNS as an adjunctive to prophylactic and 
abortive drugs in EM patients. We observed compara-
ble responsiveness for head pain severity and frequency 
[9–19]. A remarkable reduction in severe attacks was 
observed in our cohort, similiar responsiveness was 
observed for pharmacological interventions. Ferrari 
et  al. performed a meta-analysis and reported up to 
59% response rates after 2  h (improvement moderate/
severe to mild/no pain), 30% pain free state after 2 h and 
20% sustained pain free state (no headache recurrence 
or use of rescue medication 2–24  h after baseline) for 
acute pharmacological migraine interventions [8]. Most 
recently, Martelletti et  al. assessed additional secondary 
Fig. 1 a–d Pain intensity (VAS) score, migraine frequency (headache days, total number of attacks) and Pittsburgh Sleep Quality Index (PSQI) 
score at baseline (preVNS) and follow‑up (postVNS) in all patients. Mean values with Standard deviations are presented. “*” Indicate the statistical 
significance
Fig. 2 Total numbers of attacks and distribution of mild/moderate/
severe rated attack severity at baseline and post nVNS. Mean values 
with Standard deviations are presented. “*” Indicate the statistical 
significance
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outcome parameter of the PRESTO study and found 
a higher rate of pain-freedom and pain-relief attacks as 
well as a higher rate of severity reduction in migraine 
patients compared to sham stimulation [17]. This mean-
ingful improvement was accompanied by a considerable 
rescue medication decrease [18]. However, the antinoci-
ceptive head pain potential of the vagus nerve was con-
firmed in a further t-VNS study targeting the auricular 
branch at low frequencies (1 Hz) with 30% responder rate 
(responder defined as ≥ 50% reduction in headache days) 
[19]. Additionally, our feasibility study demonstrated an 
improved sleep quality with adjunctive nVNS, which is in 
line with previously published data [10, 11].
No association was found between those with excel-
lent response compared to less favorable outcome and 
specific saliva OXY and IL-1β measures. Of note, our 
study enrolled EM and CM participants, as it has been 
well documented, that both subtypes encompass differ-
ent characteristics and beyond doubt have been linked 
to different pathomechanisms [5–7]. Overweight (BMI 
25–30 kg/m2) was present in 4 out of 12 patients, thus it 
cannot be excluded, that this fact may have a considerable 
impact on the increased inflammatory levels. In contrast 
to earlier hypothesis restricting the function of white 
adipose tissue (WAT) as a metabolic storage organ, cur-
rent revised concepts consider WAT as an inflammatory 
endocrine active organ with the capability to promote or 
suppress peripheral and central inflammation via cross-
talks between adipocytes (e.g. synthesis of leptin/adi-
pokines) and the innate and adaptive immune system. 
Obesity as a low-grade chronic inflammation has been 
associated with tissue hypoxia/necrosis with consecu-
tively upregulation of the pro-inflammatory response 
via cellular (M1/2 macrophage—Th1/Th2 cells pheno-
type transformation) and molecular (IL-1β, IL-6, TNF-
α) pathways [51]. Hence, future inflammatory migraine 
Table 4 Mean values of  clinical scores at  baseline 
and post-nVNS treatment given for sleep, mood, migraine-
associated disability and quality of life
BDI Becks depression inventory, EQ-5D-5L EuroQol five-dimensional five level 
scale, MIDAS Migraine Disability Assessment, nVNS non-invasive vagus nerve 
stimulation, PSQI Pittsburgh Sleep Quality Index
Pre nVNS Post nVNS p-value
PSQI 9.6 6.7 0.02
BDI 14 12.5 0.77
MIDAS 49 38 0.44
EQ‑5D‑5L 10 9 0.64
Fig. 3 a, b Oxytocin and Interleukin‑1ß analysis (mean values with standard deviation and p‑values). Saliva measurements for Oxytocin and IL‑1ß at 
baseline (preVNS) and follow‑up (postVNS) are compared to healthy controls. Mean values with Standard deviations are presented. “*” indicate the 
statistical significance. Abbreviations: OXY Oxytocin, IL‑1ß Interleukin‑1ß, HC healthy controls, ns not significant
Fig. 4 Cumulative correlation analysis between pre‑/postnVNS OXY 
levels and nVNS outcome in headache frequency (headache days/
month). Assessment of cumulative pre‑ and post‑nVNS OXY levels 
showed a trend towards association with the headache days per 
month (r = 0.379, p = 0.08). OXY Oxytocin, IL‑1ß Interleukin‑1ß, HC 
healthy controls, ns not significant
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research should consider targeting peptides of the adi-
pokine superfamily [51].
Inter-ictal oxytocin and saliva levels were significantly 
higher in migraine patients compared to healthy con-
trols at baseline and subtly increased after nVNS. So far, 
most of the reported studies determined cytokine, not 
oxytocin, in serum and compared inter-ictal versus ictal 
cytokine signaling. Significantly increased ictal IL-1β, 
IL-6 and TNF-α serum concentrations were measured 
in migraine patients with/without aura compared to 
post-ictal (after 1  week treatment) and healthy sub-
jects not clearly indicative for a predictive value. Similar 
results were published addressed to migraine and peri-
ictal cytokine analysis [38–40]. In our trial, oxytocin and 
IL-1β screening was performed post-ictally and differed 
in the choice of the investigated biofluid (saliva). Indeed, 
it would have been of interest to collect ictal values and 
additional markers relevant for migraine such as CGRP, 
but was not performed according to our study proto-
col. As expected we found higher post-ictal concentra-
tions in migraine patients compared to healthy controls. 
In line with the findings of Perini et  al., it is likely, that 
ictally assessed saliva concentrations would have dis-
played higher values compared to our post-ictal results 
[39]. Nevertheless, elevated saliva levels of inflammatory 
markers may serve as head pain susceptibility screen-
ing tool in migraine patients. After nVNS therapy, both 
mediators further increased along with an improved 
head pain state by preventive and abortive means. On the 
one hand, the increased oxytocin levels may be driven by 
the observed marked pain relief in our cohort. In several 
experimental studies, oxytocin has been demonstrated 
to be released in response to activated sensory neu-
rons of the body (pinch, touch). In particular, electrical 
stimulation of somatic sensory neurons and afferent fib-
ers of the vagal nerves was shown to effectively increase 
oxytocin plasma levels immediately after stimulation, 
which may support the observed increased oxytocin 
levels in our VNS treated study population [52]. In addi-
tion, it is important to note, that 50% of our cohort suf-
fered from migraine-associated aura. Cortical spreading 
depression as the electrophysiological correlate of aura 
has been suspected to evoke astrocytes (microglia) 
induced synthetization and immune response via IL-1β 
among other cytokines [53]. Other human studies found 
a correlation between oxytocin concentrations and head 
pain intensity in migraine, contrary, we observed a trend 
towards association of migraine frequency (headache 
days/month) and oxytocin saliva levels [53]. On the other 
hand and to our surprise, concentrations of pro-inflam-
matory IL-1β was higher after nVNS compared to base-
line. Possible explanations may be the fact that although 
clinically improved none of the nVNS treated subjects 
could be classified as head pain free suggesting an ongo-
ing inflammatory process. Importantly, preliminary data 
indicate that intra-nasally administered oxytocin (32 IU) 
reduces pain in two patients with chronic migraine head-
ache. This effect was reduced in patients who had taken 
nonsteroidal anti-inflammatory drugs suggesting that the 
anti-nociceptive effect of oxytocin is cytokine-dependent 
[33].
Only one human study assessed possible effects of 
cervical nVNS on the peripheral components of the 
neuro-immune reflex in healthy humans. Lerman and 
colleagues measured healthy individuals randomized to 
verum and sham cervical nVNS treatment. Chemokine 
levels assessed at baseline, and at 90  min and at 24  h 
after treatment showed a decrease in pro-inflammatory 
IL-1β, IL-8, and TNF-α levels and an increase in anti-
inflammatory IL-10 levels, indicating that nVNS may 
inhibit pro-inflammatory cytokine release [41]. Other 
human studies conceptualized to determine peripheral 
inflammatory profiles of subjects treated with surgically 
implanted invasive VNS (iVNS) were limited to depres-
sion and focal seizure with limited interpretations due to 
the uncontrolled study design [36, 37]. However, compa-
rable cytokine/chemokine data under VNS “off”-stimula-
tion remain an open question.
The impact of oxytocin on trigemino-nociceptive signaling
Recently, a preclinical study determined oxytocin recep-
tor expression and co-localization with calcitonin gene-
related peptide (CGRP) in the trigeminal ganglion. 
Application of painful, facial electrocutaneous stimu-
lation and adjunctive capsaicin-driven inflammation 
increased oxytocin expression in CGRP-containing 
Fig. 5 Cumulative correlation analysis between pre‑/postnVNS OXY 
levels and nVNS outcome in headache frequency (attacks/month). 
Assessment of cumulative pre‑ and post‑nVNS OXY levels showed no 
association with number of attacks per month (r = 0.343, p = 0.12). 
OXY Oxytocin, IL‑1ß Interleukin‑1ß, HC healthy controls, ns not 
significant
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trigeminal ganglion neurons, indicating the important 
role of oxytocin in migraine pathophysiology [34].
The relationship between migraine and oxytocin was 
under investigation in a sophisticated experimental 
setting including measurement of electrophysiologi-
cal (TNC firing response) and gene expression (C-fos) 
parameters after intranasal oxytocin administration 
compared to placebo [35]. In the first, increased TNC 
firing rates after electro-cutaneous stimulation of the 
face were recorded and of note, attenuated by oxytocin, 
while in the second an increased C-fos expression in 
TNC neurons was observed after intra-peritoneal injec-
tion of nitroglycerin, which was revised in the oxytocin 
pre-treated group. In a next translational step, intranasal 
oxytocin was assessed in sham-controlled trials in EM 
and CM patients [35]. Although no significant differences 
were observed after 2 h treatment for both migraine sub-
types, the CM subgroup demonstrated a trend in favor of 
the verum treatment. Additional human trials indicate a 
stronger effect of oxytocin on frequency, rather than on 
severity. Interestingly, NSAID use was suspected to inter-
fere with oxytocin effects by inhibiting cytokine synthesis 
[35]. NSAID as an adjunctive rescue medication was pre-
sent in 5 out of 12 patients in our study.
Migraine as a multi-network brain disorder displays 
altered sensory (nociception), cognitive, affective and 
circadian-dependent autonomic features (sleep, metabo-
lism, thermoregulation), of which each component is able 
to drive head pain onset/attacks [54–56]. Apart from its 
ictal functions, inter-ictal endogenous oxytocin has been 
linked to central sensitization (hyperalgesia, allodynia) 
and neurogenic inflammation in migraine pathophysiol-
ogy. Such elevated inter-ictal oxytocin concentrations 
may reflect modulation of extracephalic pain perception 
and affective distress symptoms. Indeed, it would have 
been of great interest to quantify these inter-ical appear-
ing clinical features relevant for migraine [56]. Taken the 
complex and dynamic nature of migraine into account, 
the authors speculate, that molecular profiling of oxy-
tocin may have a diagnostic and therapeutic potential for 
migraine-associated symptoms outside the ictal phase 
[54, 55].
Pro-inflammatory IL-1 β associated effects 
in trigemino-nociceptive traffic
Zhang et al. recorded TG neuron response of meningeal 
nociceptors after local application of IL-1β and IL-6 on 
dural nociceptors and found that IL-1β, but not IL-6 was 
able to promote increased activity of TG neurons accom-
panied with increased mechano-sensitivity of intracra-
nial nociceptors (meningeal afferent signaling) measured 
von Frey filaments [42].
IL-1β has been suspected to induce upregulation of 
cyclo-oxygenase 2 mRNA (COX-2) expression in glial 
cells and neurons of the trigeminal ganglion (TG). 
These COX-2 dependent pathways lead to prostaglan-
dine release from glial and neuronal TG cells, which in 
turn stimulates solely neurons of the TG to immediately 
(1 h after stimulation) produce CGRP, contrary to IL-1β, 
which demonstrated a delayed CGRP release pattern 
(24  h after stimulation) suggesting a glia-neuron inter-
action in the TG [57]. Methylprednisolone reversed the 
IL-1β effects, but demonstrated no impact on prosta-
glandine induced CGRP release [58]. Leptin, a metabolic 
marker produced by WAT cells, has been shown to inter-
act with the COX-2 dependent pathways via crosstalks 
with IL-1β in glial cells and neurons of the hypothalamic-
pituitary axis [59].
The development of acute head pain has been associ-
ated with primary afferents activation of the TG driven 
by dural nociceptors, which are connected with the 
trigeminal nucleus caudalis (TNC). The TNC itself pro-
jects to the trigemino-cervical complex (TCC), and 
receives reciprocal input from the brainstem, the medulla 
oblongata, the hypothalamus-pituitary-axis, the thalamic 
nuclei (intralaminar nucleus of the thalamus) and cortical 
associated networks.
On the other hand, it has been well described, that the 
afferent properties of the vagus nerve project via the ncl. 
tractus solitarii to the locus coeruleus (LC), the dorsal 
raphe nucleus, the parabrachial plexus, the paraventricu-
lar nucleus of the hypothalamus and maybe directly to 
the TNC and the cervical spinal cord (trigemino-cervical 
complex, TCC). In view of the anatomic reciprocal con-
nectivity of the vagus nerve, it may be reasonable, that 
cervical nVNS may impact trigeminovascular nociceptive 
signaling of pro- and anti-inflammatory markers in dif-
ferent biofluids (plasma, saliva, cerebrospinal fluid) [20, 
21, 26–31, 34, 35, 52, 57–59].
Inhaled (olfactory nerve) and/or ingestive (trigeminal 
nerve) chemical irritants have been suspected to promote 
pro-inflammatory mediators and to trigger neurogenic 
inflammation in a broad range of respiratory (asthma) 
and neurological disorders such as migraine. A dynamic 
and complex interplay between local (e.g. substance P, 
bradykinin) and distant efferent effects (adrenergic, cho-
linergic) characterizes in part the host response, in which 
mast cell derived immunomodulation plays a pivotal role. 
Hence, it cannot be excluded, that environmental fac-
tors may have an impact on inflammatory phenotyping 
and quantification of peripheral markers of the neuro-
immune axis [60, 61].
In particular, immunomodulatory mast cells (high 
affinity receptor FceR1) are capable to interact with the 
innate and adaptive immune response and poses an 
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important role in the genesis of acute/chronic inflam-
mation associated disorders (e.g. migraine). Immun-
globuline E (Ig E), Toll-like receptors, IL-1β and IL-36 
are known to activate mast cells and to drive a pro-
inflammatory state, while IL-37 and IL-38 (member of 
the IL-1 cytokine family) act as an inhibitor of inflam-
mation. Gallenga and colleagues reported that IL-38 is 
able to bind on the IL-36 receptor, which in turn blocks 
mast cell activation [62]. It is important to note, that mast 
cell response occur in a time dependent manner with 
an immediate secretion and a delayed synthesis/release 
of inflammatory active peptides in order to establish a 
physiological host response. Among the mentioned IL-1 
cytokine family, IL-1β increases IL 33 and TNF-α synthe-
sis derived from mast cells. Furthermore, IL-33 interacts 
with monocytes and promotes mast cell differentiation, 
maturation and degranulation with subsequent secretion 
of pro-inflammatory cytokines/chemokines. Contrary, 
IL-37, an anti-inflammatory member of the IL-1 cytokine 
family, has the potential to counterbalance the IL-1β 
evoked innate and adaptive immune response. Therefore, 
the therapeutic anti-inflammatory value of IL-37 induced 
blocking of mast cells deserves further clarification in 
migraine research [63, 64].
Limitations and future prospects for molecular 
inflammatory profiling in migraine
This study has several limitations including the uncon-
trolled design, the small-scale study cohort and a rela-
tively short-term observation period. The main issue is 
related to the lack of a sham stimulation group (stimu-
lation off) in order to discern what was due to patient’s 
expectation (treatment self-responsibility) in contrast to 
the real effects of nVNS. With respect to migraine as a 
complex brain disorder, such expectation associated with 
a novel device (like nVNS in our study) may represent a 
confounder. Different dosages of migraine drugs (preven-
tive/abortive) administered in each patient may represent 
a confounder. Furthermore, cytokine levels may vary and 
depend on pre-analytic variables including sample pro-
cessing, environmental factors, intra- and interindividual 
variability. The cytokine analysis performed in our study 
did not consider the dynamic nature of neuro-inflam-
mation nor the circadian neurobiology, thus repetitive 
measurements are recommended in future trials. The 
role of the brain-immune-communication in primary 
headache disorders is of major interests. To this end, 
immune-phenotyping of migraine is in the beginning. 
Future research in this field should seek to investigate 
which immune pathways are overactivated in migraine, 
how immune cell hyperactivity is linked to disease sus-
ceptibility, and how environmental and genetic factors 
influence immune activation and disease manifestation. 
Immune-phenotyping should consider cell profiling in 
several flow cytometry panels and whole blood stimula-
tion assays with a range of innate immune stimuli. Can we 
use molecular profiling to predict and individualize neu-
rostimulation (nVNS) therapy? Can we target cytokines 
as diagnostic tools? Currently the answer is no as the 
precise mechanisms of the neuro-immune communica-
tion in migraine pathophysiology remains unclarified. 
Alternatively, advanced statistical methods capable to 
establish categorical-based dimensions may support the 
potential and the integration of biobank-based immune-
phenotyping, thus help to define migraine specific char-
acteristics and subsets (biotypes) of patients more or less 
likely to respond to neurostimulation therapy [65, 66]. 
However, this study firstly approached to screen oxytocin 
and IL-1β in saliva and attempted to proof the feasibility 
of saliva analysis and undoubtedly, but was biased by the 
uncontrolled study design.
Conclusion
Ten weeks of adjunct nVNS therapy significantly 
decreased migraine severity and frequency in patients 
with EM (with/without aura). In addition, migraine-asso-
ciated sleep impairment was improved. Inter-ictal saliva 
concentrations of oxytocin and IL-1β were significantly 
higher in migraine patients compared to healthy controls. 
An evidence-derived conclusion about the predictive 
value and usefulness of saliva assays is clearly limited by 
the provided uncontrolled study design. Clearly, our find-
ings along with preclinical and human available literature 
data point to the necessity to monitor changes in a broad 
array of anti- and pro-inflammatory markers during 
nVNS since treatment effects may be reflected in altered 
ratios of different markers. Thus, the observed salivary 
levels (and nVNS-induced changes) must be interpreted 
with caution and currently remain at an experimental 
stage (feasibility). However, the assessment of cytokine/
chemokine plasma and/or saliva levels addressing the 
pathogenesis and treatment of migraine may represent 
a novel approach and may be worthy for being re-visited 
under controlled study condition in order to evaluate its 
usefulness beyond subjective patient´s self-report.
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